Cara Therapeutics v EUIPO - Gebro Holding (KORSUVA) (EU trade mark - Judgment) [2021] EUECJ T-584/20 (08 September 2021)

Cara Therapeutics v EUIPO - Gebro Holding (KORSUVA) (EU trade mark - Judgment) [2021] EUECJ T-584/20 (08 September 2021)

The Board of Appeal correctly found an average degree of visual and phonetic similarity between KORSUVA and AROSUVA, identity of goods, and an average degree of distinctiveness of the earlier mark. These factors, even considering the high level of attention of the relevant public, result in a likelihood of confusion...

Source-derived case information.

Citation
[2021] EUECJ T-584/20
Parties
Applicant: Cara Therapeutics, Inc.; Intervener: Gebro Holding GmbH; Respondent: European Union Intellectual Property Office (EUIPO)
Jurisdiction
European Union
Procedural Posture
EU Trade Mark Opposition Appeal / Judgment of the General Court (second Chamber)
Outcome
Action dismissed
Legal Topics
Trade Marks, Likelihood of Confusion, Opposition Proceedings, Visual and Phonetic Similarity, Distinctiveness
Intellectual Property Trade Marks Likelihood of Confusion Opposition Proceedings Visual and Phonetic Similarity Distinctiveness

Source-derived case record

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Downloadable case file Legal principles 4 Authorities cited 20 Party arguments 2
Sign in to unlock

Parties

Cara Therapeutics, Inc.

Applicant

Gebro Holding GmbH

Intervener

European Union Intellectual Property Office (EUIPO)

Respondent

Procedural Posture

EU Trade Mark Opposition Appeal / Judgment of the General Court (second Chamber)

  1. 1 Whether the Board of Appeal erred in finding a likelihood of confusion between the marks KORSUVA and AROSUVA under Article 8(1)(b) of Regulation 2017/1001

Ratio Decidendi

The Board of Appeal correctly found an average degree of visual and phonetic similarity between KORSUVA and AROSUVA, identity of goods, and an average degree of distinctiveness of the earlier mark. These factors, even considering the high level of attention of the relevant public, result in a likelihood of confusion under Article 8(1)(b) of Regulation 2017/1001. The applicant's arguments do not undermine this assessment.

Court Disposition

Action dismissed

Orders

  • Dismisses the action
  • Orders Cara Therapeutics, Inc. to pay the costs